Who We Are
Lucence Diagnostics is a genomic medicine company focused on personalizing cancer care. We invent a full spectrum of cancer diagnostics covering early-stage screening to late-stage treatment selection with a special focus on common cancers in Asia. We are headquartered in Singapore, with offices in San Francisco and Hong Kong. We are supported by a central accredited molecular diagnostics laboratory.
A world without avoidable cancer deaths.
To achieve early cancer detection, better treatment and less suffering through deep genome intelligence.
We see the fight against cancer as a mission. If we can deliver early detection for all cancers to achieve cure, that is something worth our time, our energy, everything.
The story of Lucence Diagnostics began in 1999, when our founder Dr Min-Han Tan (Han) was a medical resident at the university cancer center in Singapore. There he witnessed great suffering, but also saw the ability of modern medicine to alleviate unnecessary pain and distress. This formative experience motivated him to focus his life and career on understanding how to fight and defeat cancer through a deep understanding of the human genome. Han believes that oncology exists where bedside medicine, high technology, deep research and profound spirituality intersect.
Han first completed his medical oncology specialist training. He then went on to pursue his PhD in cancer genetics at the Karolinska Institute, Sweden and the National University of Singapore. To seek deeper understanding on genomic medicine, Han joined the Cleveland Clinic in the United States as a research scholar, where he was awarded both the Lee Foundation and Ambrose Monell Cancer Genomic Medicine. At the Cleveland Clinic, he and Professor Charis Eng published landmark data models on cancer risk in hereditary breast and thyroid cancer diseases. This work continues to guide the international cancer community in patient care today.
In 2011, Han joined the Agency for Science, Technology and Research (A*STAR) to lead the Laboratory of Systems Medicine and focus on building better genomic technology for cancer patients. Over the next 5 years, Han and his team made key discoveries on the nature of circulating tumor-derived DNA and circulating cancer cells by applying innovative laboratory and machine-learning technologies. His discovery of the circulating tumor-endothelial cluster transformed the liquid biopsy field and overturned decades of scientific dogma. This research led to improved non-invasive screening and profiling of cancer using blood testing.
Han founded Lucence in 2016 to deliver his genomic technology from the laboratory to the world where it was most needed. Lucence’s vision is a world without avoidable cancer deaths through early cancer detection and better treatment selection. The company’s AmpliMARK™ sequencing technology is used in its flagship liquid biopsy test, LiquidHALLMARK®, for the detection of multiple cancer-causing mutations and viruses. Its SunTzu.AI™ machine-learning platform centralizes genomic intelligence and maps cancer fighting strategies for individual patients.
Today Lucence has expanded to a 10,000 square foot headquarters in Singapore, with offices in San Francisco and Hong Kong. Its liquid biopsy technology is available in 8 countries across Asia to help doctors reduce the pain and sufferings of cancer patients.
Achieving a world without avoidable cancer deaths through genomic intelligence is at the core of everything Lucence does.
Licensed as clinical laboratory by Singapore’s Ministry of Health
ISO 15189 accreditation for Singapore laboratory
Opened cancer genetics clinic in Singapore
Company expands to Hong Kong
Company expands to San Francisco
We are a venture-backed company with the mission to fight cancer through earlier diagnosis and earlier treatment. To realise our vision, we have assembled a team of like-minded investors with an understanding of how great technology is nurtured and developed, the positive impact it can have on lives, and make a real difference to humanity.
We partner with healthcare providers and medical laboratories to deliver our cancer diagnostic services in Singapore and the region. We also collaborate with pharmaceutical companies, hospitals, medical centres and academic institutions to conduct research studies that advance the field of genomic medicine.
CEO and Medical Director
Min-Han (Han) is the Founder, CEO and Medical Director of Lucence Diagnostics. A trained medical oncologist and clinical cancer geneticist, he received his MBBS in 1998 and PhD in molecular epidemiology and biostatistics in 2011 from National University of Singapore. He completed his cancer specialist training at the National Cancer Centre Singapore (NCCS). He obtained the Gerber Foundation and Lee Foundation Fellowships to pursue cancer genetics fellowships at the Van Andel Research Institute, Michigan in 2003 and the Cleveland Clinic, Ohio in 2010, respectively. In 2011, He joined the Agency for Science, Technology and Research (A*STAR) in Singapore to lead the Laboratory of Systems Medicine. Han started Lucence in March 2016 to commercialize the genomic technologies that his lab developed at A*STAR.
Han has published over 100 original research publications spanning diverse interests in basic, translational, clinical, public health and policy, and filed more than 12 patents with inventions licensed and deployed in laboratories worldwide. He is recognized internationally for his landmark discovery of circulating tumor-endothelial cell clusters in the blood of cancer patients, which overturned a 50-year scientific dogma. Han also established the international diagnostic criteria and lifetime cancer risks for Cowden syndrome, a hereditary breast cancer syndrome, and led a breast cancer screening research study involving over 29,000 individuals followed up over 20 years.
For his track record of disruptive innovation in research and clinical medicine, Han has been recognized with awards from the American Society of Clinical Oncology, the European Society of Medical Oncology and the Association of Southeast Asian Nations. He was elected Fellow of the Royal College of Physicians Edinburgh in 2015 and received the A*STAR Outstanding Scientist-Entrepreneur Award in 2018.
Chief Technology Officer
Yukti is the Chief Technology Officer and co-founder of Lucence Diagnostics. A molecular biologist by training, Yukti holds a BSc (first class honors) and a PhD from the National University of Singapore. At Lucence, Yukti is responsible for creating new molecular diagnostic technology for cancer detection and treatment. She leads a team of scientists and data professionals who harness the genomic information of patients for better clinical decision-making. Prior to Lucence, she was a research scientist at the Agency for Science, Technology and Research (A*STAR) in Singapore. At A*STAR, Yukti made major breakthroughs by discovering new treatment targets in brain and kidney cancers. Notably, she accomplished the first ever patient-specific, stem cell-based method for modeling drug-induced liver toxicity. She has been recognized for her scientific contributions by the American Society of Clinical Oncology and was named a “Promising Young Investigator” by the Kidney Cancer Association in 2016.
Chief Commercial Officer
Pan is the Chief Commercial Officer and co-founder of Lucence Diagnostics. She leads the commercialization efforts in bringing our best-in-class cancer diagnostic tests from bench to bedside at Lucence. She is an advocate for precision medicine and genetic testing. Trained as a microbiologist, Pan has been working in the field of molecular diagnostics focusing on oncology and infectious diseases for over 10 years. Prior to Lucence, Pan led the sales and marketing operations for multinational diagnostics companies across the United States, Europe, China and Southeast Asia. She has also successfully developed and commercialized several cutting-edge diagnostic tools and methods. Pan holds a PhD in Microbiology from the National University of Singapore.
Chief Financial Officer
Kevin comes with over 10 years of experience in accounting, assurance and taxation. He oversees the financial planning and infrastructure of the company. His assurance background with KPMG has given him a keen understanding of company growth, compliance needs and project management. In his previous role as the Financial Controller of a listed healthcare company, he developed his skills in operations and workflow management. He is a chartered accountant and holds a Bachelor’s degree in Accountancy from Nanyang Technological University. Kevin is a seven-time Singapore national chess champion and a globally recognised chess writer. He is on the verge of becoming Singapore’s second chess Grandmaster.
Wai Min Phyo
Director, Assays Development
Wai Min drives assay development and quality at Lucence. Trained in medicine and engineering, he has a track record of successful technology licensing to industry. Prior to Lucence, Wai Min worked at Dr Min-Han Tan’s lab at the Agency for Science, Technology and Research (A*STAR) where he developed novel PCR-based diagnostics that have been commercialized for real-world clinical usage. He was also instrumental in setting up a tissue bank for research and development in colorectal cancer, a collaboration between A*STAR and Fortis Colorectal Hospital. He holds an MBBS from University of Medicine (I), Yangon and a Master’s degree in Engineering from National University of Singapore.
Jess oversees the operational matters and manages key projects at Lucence. She is adept at navigating business growth and operations with her profound understanding of team dynamics. Prior to joining Lucence, she worked in Dr Min-Han Tan’s lab at the Agency for Science, Technology and Research (A*STAR). There, she led and published several key research studies in cancer diagnostics and liquid biopsies. She co-invented a liquid biopsy test that detects early-stage nasopharyngeal cancer which has been commercialised at Lucence. Jess has also been key in the successful filing of new patents at Lucence with her experience in intellectual property management. She graduated with a BSc (Hons) in Biological Sciences from Nanyang Technological University.
Hao creates the core algorithms powering our complex analytics yielding the best possible diagnostic services for our patients. He has an accomplished track record of creating world-class, highly innovative software platforms for analyzing biological and cellular diversity at the Agency for Science, Technology and Research (A*STAR). Regularly ranked among the top downloads on Bioconductor (the primary open-source biological software repository in the world), his algorithms provide insights in high-dimensional and high-throughput single-cell complex data analysis. Hao’s work has been published in top peer-reviewed journals, and he has filed patents on technology for automated and reproducible analysis of complex data. He received his BSc in Biotechnology from the Harbin Institute of Technology (China) and MSc in Bioinformatics from the Nanyang Technology University (Singapore).
Director, Healthcare Analytics
As Director of Healthcare Analytics, Jack is responsible for organizing the diverse data streams that empower cancer patients and providers to make the best treatment decisions possible. Based in San Francisco, he also helps Lucence maximize research and commercial opportunities in the United States. An entrepreneur at heart, Jack previously co-founded CliniCast – a startup that helped providers in the US and Singapore organize complex cancer information for research and patient treatment. After Elekta acquired CliniCast in 2015, he helped grow Elekta’s operational analytics portfolio to a global customer base. Jack holds a PhD in Physics from Yale University.
Benson oversees the legal aspects of our multi-jurisdictional and rapidly growing businesses. He is called to the Singapore Bar and admitted as a solicitor in England and Wales. Bensons holds an LLB from the National University of Singapore. He speaks English and Mandarin Chinese.
Director, Corporate Strategy
Jessie joins the company with over 13 years of experience as an equity research analyst, portfolio manager, and director of sales at various Wall Street firms. Most recently she served as strategy advisor to the CEO of Genomic Personalized Health, a whole genome sequencing service provider. Her professional background has provided her with a strong foundation in strategic and analytical thinking, as well as effective communication, project management and leadership skills. Jessie is a chartered financial analyst (CFA) and holds a Master’s degree in Management Science from Stanford University Graduate School of Business and a Bachelor’s degree in Finance and Econometrics from University of New South Wales in Sydney. Jessie is also a certified yoga instructor.
Elena has more than 16 years of corporate communications experience in the public and private sectors. She brings significant experience dealing with the medical technology and research sectors to Lucence. Most recently, she was the head of corporate communications at the Agency for Science, Technology and Research (A*STAR). In that role, she was responsible for external and internal communications for over 150 scientists. She has also held positions in the private sector with Ogilvy Public Relations, GolinHarris, Asurion and Pacific Internet. Elena holds a BA in English Language and Sociology from the National University of Singapore.
Jamen is the country manager of Lucence’s Hong Kong office. He manages all aspects of the operations to effectively deliver our cancer diagnostic services to healthcare providers in Hong Kong. Prior to heading up the Hong Kong office, Jamen was the Director of Marketing at Lucence’s Singapore headquarters. He comes with strong entrepreneurship experience, having started and managed four companies across various industries such as medical logistics, travel, education and events management. This has equipped Jamen with the know-how of building business viability and profitability. He holds a BEng from the National University of Singapore.
Director, Product Management
Hilary is responsible for product management at Lucence, and account management in Hong Kong. With her deep expertise in both commercial and technical aspects of biotechnology, she focuses on delivering our flagship liquid biopsy testing to physicians and patients for best outcomes. Hilary has had extensive international experience growing medical diagnostics across Asia, Europe, Africa, Middle East and Latin America. She holds a BSc in Biological Sciences from The University of Hong Kong and a MSc in Marketing from City University of Hong Kong.
Senior Sales Manager,
Jack is the Senior Sales Manager at Lucence’s Hong Kong office. She comes with extensive oncology sales experience in the pharmaceutical industry, covering the hospitals and clinics in Hong Kong and Macau. Prior to Lucence, she was a customer liaison manager at Innovative Diagnostics. At Lucence, she is responsible for promoting the adoption of our cancer diagnostic tests among the medical professionals in Hong Kong. Jack has a certificate in Nursing from The Grantham Hospital, Hong Kong.
Head of Rep. Office, Vietnam
Mai Nguyen is responsible for Lucence’s business operations in Vietnam. She has extensive experience in office management, project construction, marketing, and media. Mai’s previous industry touchpoints include office-for-lease and real estate sectors in Vietnam. She holds a Bachelor of Business Administration from Văn Hiến University.
Hilda is the Business Development Manager at Lucence. She is responsible for expanding our business operations to new markets in Asia. Hilda has extensive frontline experience in the healthcare and biomedical sectors, which enables her to build strong working relationships with new and existing customers. She graduated with a BSc in Biomedical Sciences from the University of Bradford. Hilda holds a BSc in Biomedical Sciences from the University of Bradford.
Kim Tien Ng
Kim Tien is the Scientific Officer at Lucence Diagnostics, where his main role includes scaling up robotic process automation to improve operational efficiency, productivity and quality. He holds a PhD in Medical Virology and Molecular Epidemiology from the University of Malaya, during which he developed and patented an improved assay for rhinovirus (RV) quantification. He has received several international Young Scientist Awards in the US, Germany and Japan for his research on the identification and characterization of novel HIV-1 recombinants and the investigation of HIV-1 transmission networks in Southeast Asia. Prior to Lucence, he was a Research Associate at the Duke-NUS Medical School, where he designed the viral and bacterial peptide libraries for potential real-life application in combating disease outbreaks.
People & Organisational Development
People & Organisational Development
Yvonne focuses on people development and organisational effectiveness at Lucence. She holds a Bachelor of Arts from Kyoto University and is proficient in Japanese. Yvonne enjoys learning foreign languages and being a part of multicultural environments.
Daniel Tan Kian Hin
Daniel did his postgraduate study in the University of Malaya after the completion of his undergraduate education in the same university. During his postgraduate candidature, he focused on the study of quorum sensing, a form of bacterial communication in an uncommonly studied bacterium, Cedecea neteri. Being driven by his interest in the application of next-generation sequencing (NGS) for clinical research, he joined Lucence Diagnostics. He is now involved in the development and validation of NGS assays.
Siti Farah Bte Fadhlullah
Farah graduated with a BSc (first class honors) in Biological Sciences from Nanyang Technological University. At Lucence, she develops cancer diagnostic assays utilizing advanced sequencing technology. Farah has conducted liquid biopsy research at the Agency for Science, Technology and Research (A*STAR) and brain cancer treatment research at the National Neuroscience Institute (NNI). She has won numerous awards in her early scientific career, including the Promising Young Researcher Award from A*STAR and the Best Junior Research Presentation Award from NNI’s Academic Clinical Program.
After graduating with a BSc in Biological Sciences from Nanyang Technological University, Joyce ventured into cancer genomics research in circulating tumor cells at the Agency for Science, Technology and Research (A*STAR). She has a keen interest in translational research to bridge findings from the bench to bedside. At Lucence, Joyce is responsible for medical diagnostic testing and helps to maintain workplace health and safety. She holds a MSc in Safety, Health and Environmental Technology from the National University of Singapore.
Albert Ho Yi Liang
Full Stack Engineer
Yi Liang is responsible for developing an automated workflow management system and data analysis platform at Lucence to enhance the delivery of our cancer diagnostic services. Prior to Lucence, he was a researcher at Nanyang Technological University, where he worked on natural language processing to build next-generation search engines such as ontology search. Yi Liang embraces new technologies like augmented reality, blockchain and Smart Home because he believes that great technology makes life better. He received his BBA from the Harbin Institute of Technology and graduate diploma in Systems Analysis from the National University of Singapore.
Michelle is involved in the development of diagnostic assays and clinical reporting. Prior to Lucence, she worked at the Agency of Science, Technology and Research (A*STAR) where she investigated combinatorial targeted therapy in colorectal cancer, and optimized the use of preclinical cancer models for drug development using next-generation sequencing. Michelle was awarded the A*STAR Graduate Scholarship to pursue her PhD in Cancer Biology from the National University of Singapore. She holds a BSc (Hon) in Biological Sciences from Nanyang Technological University.
Thet Naing Aye
Naing is responsible for developing clinical intelligence software applications and services at Lucence. He is passionate about software development and building applications based on best engineering practices. Naing holds a MSc in Construction Management from Nanyang Technology University and BE in Naval Architecture from Myanmar Maritime University. He also has a graduate diploma in Systems Analysis from the Institute of Systems Science, National University of Singapore.
Yong Herng Low
Yong Herng oversees laboratory management at Lucence. He played a key role in achieving Lucence’s early milestones of clinical laboratory licensing from the Singapore’s Ministry of Health and ISO 15189 accreditation. Yong Herng joined Lucence from the Singapore General Hospital, where he was a key operator of the External Quality Assurance Program and Safety Program for its biochemistry laboratory. With his background as an underwater combat medic for Singapore’s elite Naval Diving Unit, Yong Herng is skilled in working with highly focused teams to solve complex operational problems. He graduated with a BSc (first class honors) in Medical Bioscience from Aston University.
Deputy Laboratory Manager
Melvin is responsible for maintaining adherence to laboratory protocol and test quality control management. Prior to joining Lucence, he was a research officer at the Khoo Teck Puat Hospital for 8 years. There, he contributed significantly to numerous cohort study publications on endocrinology, focusing on Type 2 Diabetes and obesity. Being at the forefront of clinical research, Melvin has gained extensive experience in analytical methods for proteomic biomarker studies. He is also well equipped with next-generation sequencing skills. He holds a BSc in Biomedical Sciences from the University of Western Australia.
Michelle Tan Bee Kim
Senior Medical Technologist
Michelle is a Senior Medical Technologist at Lucence Diagnostics. She has extensive experience in genomic testing, particularly in companion diagnostics. Prior to Lucence, she was a medical technologist at the Singapore General Hospital and a contract research organisation. At Lucence, Michelle conducts molecular diagnostic testing on human biological specimens. She has a BSc (Hons) in Biological and Biomedical Sciences from Nanyang Technological Universit
Medical Laboratory Technologist
Marielle performs analysis of patient samples for the various assays offered at Lucence. Prior to Lucence, she was a Medical Technologist at Covance Asia, where she handled the validation of new instruments and assays. She has also worked at Axil Scientific as a Laboratory Officer for Sequencing where she handled the optimization of PCR conditions to deliver higher quality results in a shorter turnaround time. She has a certificate in Basic Industrial Safety and Health Course for Supervisors. Marielle holds a Diploma in Molecular Biotechnology from Nanyang Polytechnic.
Medical Laboratory Technologist
Mai joins Lucence after obtaining her Bachelor of Engineering (Biomedical) at National University of Singapore. Prior to Lucence, she has helped developed PCR-based diagnostic assays at A*STAR under its youth research program and designed bioresorbable bone implants for Osteopore International Pte Ltd as a Product Development Intern. Mai has an interest in public health and volunteers regularly for Project X, a non-governmental organization that promotes women’s health in Singapore.
Lay Kheng Tan
Lay Kheng oversees the operations at Lucence’s Genetics Clinic in Singapore. She takes care of the day to day operational matters to ensure the smooth running of the clinic. With her skilled background in nursing and experience caring for patients with genetic disorders of cancer and eyes, she helps to make a positive impact in the lives of our patients. She has a diploma in nursing from Nanyang Polytechnic.
Ru Jin Tay
Ru Jin is a cancer genetics counselor at Lucence’s Genetics Clinic in Singapore. She supports Dr. Min-Han Tan in providing genetic counselling to patients in Singapore and the region. Prior to joining Lucence, Ru Jin was a medical technologist at Singapore General Hospital. She graduated with a BSc in Life Sciences from the National University of Singapore.
Jennifer assists the Chief Financial Officer in accounting and procurement matters at Lucence. She graduated with a BSc in Accounting and Finance (Hons) from Singapore Management Institute. Jennifer is an avid Yoga practitioner and believes in the conscientious practice of diligence in both life and work.
Marketing Communications Executive
After obtaining her Bachelor’s degree in Engineering (Biomedical) from the National University of Singapore, Yuzhen joined Lucence to support the execution of the company’s communications and marketing initiatives. While in university, she did an internship with GE Healthcare as a Clinical Marketing Specialist, which exposed her to healthcare marketing. Yuzhen is a competitive volleyball player.
Join Our Team
Lucence is a fast-growing genomic medicine company with offices in Singapore, San Francisco and Hong Kong.
We have assembled a dynamic team of physicians, scientists, technologists, geneticists, bioinformaticians and data analysts passionate about the work we do here to improve cancer care. We come from different backgrounds and nationalities but are focused on a single mission – to fight cancer and save lives.
Join our team to transform the way we fight cancer.
Click here to view our open positions.
211 Henderson Road, #04-02
Henderson Industrial Park
Tel: +65 6909 0390
Fax: +65 6725 0590
Genetics Clinic6 Napier Road, #04-03
Gleneagles Medical Centre
Tel: +65 6592 5102
Hong Kong Office
Rooms 05-15, 13A/F, South Tower
World Finance Centre
Harbour City, 17 Canton Road
Tsim Sha Tsui, Kowloon
Tel: +852 5801 2340
Fax: +852 3012 9866
San Francisco Office
162 South Park Street
We have received your enquiry, and will get back to you soon.